Interest in microbiome-based therapies continues to accelerate across global life sciences markets. As scientific understanding of the human microbiome expands, developers are increasingly exploring microbiome-based medicinal products (MMPs) as potential treatments for a wide range of diseases.
Regulatory inspections are a routine and essential part of operating in highly regulated industries. For organizations operating in life sciences, pharmaceuticals, medical devices, and other regulated sectors, inspection outcomes can have significant operational and commercial implications.
Artificial intelligence is rapidly transforming how organizations operate. From predictive analytics and automated decision-making to intelligent manufacturing and digital health platforms, AI is now embedded across industries. As adoption accelerates, regulators and policymakers are increasingly focused on one critical issue: AI governance.
The U.S. Food and Drug Administration (FDA) released draft guidance proposing a new regulatory framework for individualized therapies targeting ultra-rare diseases. The proposed “plausible mechanism” pathway would allow certain gene-targeted drugs and biologics to pursue accelerated or traditional approval based on strong mechanistic rationale supported by focused clinical evidence.
In 2026, regulators across the globe are placing renewed emphasis on one critical foundation of compliance: data integrity. As digital systems, automation, artificial intelligence, and remote operations become more embedded across regulated sectors, agencies are signaling that data reliability, traceability, and governance are no longer operational concerns — they are executive priorities.
As pandemic risk remains one of the most consequential global threats, leaders from the World Economic Forum Annual Meeting 2026 spotlighted a pivotal shift: artificial intelligence (AI) is no longer just a tool for analysis — it’s becoming an integral infrastructure for infectious disease preparedness and response.
Telemedicine has evolved from a supplemental offering into a foundational component of modern healthcare delivery. Virtual consultations, remote diagnostics, and digital patient engagement have improved access to care, reduced logistical barriers, and supported continuity across care settings. These technologies have become especially valuable in addressing workforce shortages and extending care to underserved populations.
The FDA’s Center for Biologics Evaluation and Research (CBER) has published its proposed guidance agenda for 2026, offering an early look at the regulatory areas that will shape biologics oversight in the coming year. The agenda highlights a strong focus on cell and gene therapies, blood and blood components, vaccines, and advanced manufacturing and inspection readiness.
The U.S. Food and Drug Administration has released a new draft guidance outlining how sponsors can use Bayesian statistical methods to support the safety and effectiveness of drugs throughout clinical development. The guidance applies broadly to investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and certain supplemental applications.
As global regulatory coordination becomes increasingly important for medical device manufacturers, IMDRF’s updated strategy offers insight into how international expectations may continue to align across markets.